Piqray (alpelisib) — United Healthcare
Breast cancer
Initial criteria
- Diagnosis of breast cancer
- Advanced OR Metastatic disease
- Disease is hormone receptor (HR)-positive
- Disease is human epidermal growth factor receptor 2 (HER2)-negative
- Presence of one or more PIK3CA mutations
- Used in combination with fulvestrant
- Disease has progressed on or after an endocrine-based regimen
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Piqray therapy
Approval duration
12 months